^
Association details:
| Biomarker: | TNFRSF17 elevation + Chr t(14;16) |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Ruxolitinib and Methylprednisolone for Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Published date:
11/03/2022
Excerpt:
The results in this study among patients who received RUX and MP without lenalidomide also showed that higher baseline sBCMA levels (p = 0.0096) and, in addition, t(14;16) (p = 0.0071) predicted shorter PFS...The results of this clinical trial showed that the combination of RUX 15 mg twice daily with methylprednisolone 40 mg every other day was well tolerated and demonstrated significant clinical activity among heavily previously treated patients with multiple myeloma.
Secondary therapy:
methylprednisolone oral
DOI:
10.1182/blood-2022-163872
